Phage therapy program
BiomX / former Adaptive Phage Therapeutics (PhageBank)
| Status | Historical/inactive |
|---|---|
| Type | Company |
| Location | Former APT operations: Gaithersburg, Maryland; United States / Israel |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Do not advertise the former PhageBank/BX004 program as a current therapy access route based on older pages or registry status. |
|---|---|
| Areas of work | BiomX's July 2026 SEC prospectus reports legacy phage operations substantially discontinued and a defense/security strategy pivot. BX004 phase 2b was discontinued December 8, 2025; former Israeli operating company entered insolvency, and APT facility lease ended December 31, 2025. |
| International access | No public international-patient eligibility or acceptance policy verified. |
What to confirm
- Registry-company conflict is material: RECRUITING is stale relative to the newer discontinuation disclosure. Future ownership, transfer or availability of legacy phage assets not established.
Related studies(3)
Bacteriophage Therapy in Patients With Prosthetic Joint Infections
Withdrawn
Recorded program–study link. Website
ACTIVE2
Withdrawn
Recorded program–study link. Website
Study With Phage for CF Subjects With Pseudomonas Lung Infection
Conflicting status
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- BiomX July 13, 2026 prospectus
- NCT06998043 — ClinicalTrials.gov
- NCT05269134 — ClinicalTrials.gov
- NCT04787250 — ClinicalTrials.gov
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | biomx-apt-phagebank |
|---|